Alnylam PharmaceuticalsLTS:0HD2 67 Days Inventory is 36.03 as of Mar. 2026, which is 84% below its 10-year median of 221.59. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $517.19 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, Alnylam Pharmaceuticals ranks better than 90.75% on this metric.
The historical rank and industry rank for Alnylam Pharmaceuticals's Days Inventory or its related term are showing as below:
LTS:0HD2'
s Days Inventory Range Over the Past 10 Years
Min: 33.7 Med: 221.59 Max: 4875.04
Current: 33.7
During the past 13 years, Alnylam Pharmaceuticals's highest Days Inventory was 4875.04. The lowest was 33.70. And the median was 221.59.
LTS:0HD2's Days Inventory is ranked better than 90.75% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs LTS:0HD2: 33.70
Alnylam Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (92.54) to Mar. 2026 (36.03).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Alnylam Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.53.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alnylam Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.07.
Alnylam Pharmaceuticals (LTS:0HD2) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Alnylam Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alnylam Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Alnylam Pharmaceuticals Days Inventory Related Terms
Alnylam Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Days Inventory of 36.03 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alnylam Pharmaceuticals and its competitors. This is 84% below median its historical median of 221.59. Over the past decade, Alnylam Pharmaceuticals' Days Inventory has ranged from 33.70 to 4,875.04. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #59 out of 638 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Alnylam Pharmaceuticals' Days Inventory too high?
Alnylam Pharmaceuticals' current Days Inventory of 36.03 is 84% below median its 10-year median of 221.59. Over the past 10 years, this metric has ranged from a low of 33.70 to a high of 4,875.04. The Biotechnology industry median Days Inventory is 183.88. Alnylam Pharmaceuticals' value of 36.03 is 80.4% below this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #59 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Days Inventory compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #59 out of 638 companies for Days Inventory. This places Alnylam Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.88. Alnylam Pharmaceuticals' value of 36.03 is 80.4% below this benchmark. Historically, Alnylam Pharmaceuticals' own Days Inventory has ranged from 33.70 to 4,875.04 over the past decade. While the company's 10-year median is 221.59 vs. the industry median of 183.88, Alnylam Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Days Inventory of 36.03 is 80.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Days Inventory is 36.03, which is 84% below median its own 10-year median of 221.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.19, compared to a current price of $312.13 — trading 39.6% below its estimated fair value. The current Days Inventory is 36.03, which is 84% below median its 10-year median of 221.59 and 80.4% below the Biotechnology industry median of 183.88. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Days Inventory is 36.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $312.13 is trading 39.6% below its estimated GF Value™ of $517.19.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Days Inventory: 36.03 (84% below median its 10-year median of 221.59)
GF Value™: $517.19 vs. price of $312.13 (39.6% below fair value)
Industry Position: 80.4% below the Biotechnology median (#59 of 638)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
